IFNα1b联合阿德福韦酯治疗慢性乙型病毒性肝炎疗效观察

Clinical Observation of the Efficacy of Interferon α-lb（Hapgen） Combined with Adefir Dipivoxil for the Treatment of Chronic Hepatitis B

【目的】观察干扰素αlb（IFNαlb）联合阿德福韦酯治疗慢性乙型肝炎（CHB）的效果。【方法】CHB患者80例，分为联合治疗组42人和对照治疗组38人。观察两组患者的肝功能、HBVDNA水平、乙肝病毒标志物的变化及不良反应，所有患者均随访1年。【结果】联合治疗组的完全应答率、HBeAg的阴转率及HBV-DNA阴转率均明显高于对照治疗组；随访结束时联合治疗组的完全应答率、HBeAg的阴转率及HBV-DNA历转率仍明显高于对照治疗组；不良反应一般不需作特殊处理，并能很快恢复正常。【结论】】FNαlb联合阿德福韦酯对HBV的复制有明显的抑制作用，可加速乙肝患者HBeAg自然阴转过程，是治疗慢性乙型藕毒性肝炎有效且安全的方法。

[Objective] To observe the efficacy of Hapgen（IFNαlb） combined with adefovir dipivoxil for the treatment of chronic hepatitis B（CHB）. [Methods] Eighty CHB patients were divided into combination therapy group（ n =42） and control group（ n =38）. Liver function, HBV-DNA level, the change of hepatitis B virus markers and side effects were observed. All patients were followed up for a year. [Results] In combination therapy group, the complete response rate, negative conversion rate of HBeAg and HBV-DNA were significantly higher than those in control group at the end of treatment and at the end of follow-up. The side effects could be recovered quickly without special treatment. [Conclusion] IFNα-lb combined with adefovir dipivoxil can obviously inhibit the replication of HBV and accelerate the spontaneous negative conversion of HBeAg of CHB patients. Therefore it is an effective and safe method for treating CHB.